Clinical Trials Logo

Acute Ischaemic Stroke clinical trials

View clinical trials related to Acute Ischaemic Stroke.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06379464 Recruiting - Depression Clinical Trials

Screening of New Markers of Gut Microbiota in Stroke and Depression: a Cross-sectional Study

Start date: September 1, 2023
Phase:
Study type: Observational

Objectives of Study: Through the cross-sectional study of stroke and depression, key biomarkers are targeted by screening disease-associated intestinal bacteria, metabolites and immune factors through multi-omics techniques.

NCT ID: NCT03639922 Recruiting - Clinical trials for Acute Ischaemic Stroke

Imatinib in Acute Ischaemic Stroke

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

A clinical trial comparing treatment with Imatinib to placebo when administered within 8 hours of stroke onset for 6 days, in addition to conventional stroke treatment after acute ischaemic stroke.

NCT ID: NCT01207336 Recruiting - Clinical trials for Acute Ischaemic Stroke

Combined tDCS+PNS After Acute Stroke

Start date: September 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Recent work showed that application of peripheral nerve and cortical stimulation independently can induce 10-15 % improvement in motor performance in patients with chronic stroke. The purpose of this study was to compare in post-stroke hemiplegic patients the effect on motor recovery of one session of anodal transcranial direct current stimulation to the ipsilesional primary motor cortex (M1) combined with a peripheral radial nerve electrical stimulation (rEPNS) to the paretic hand repeated 5 successive days with the effect of the same peripheral nerve stimulation combined with sham tDCS. Design: randomized, double-blind, parallel controlled clinical trial. Patients eligible for the study: Acute ischaemic stroke Primary outcome measure: Jebsen Taylor test Secondary outcome measures Nine peg hole test Hand tapping grip and wrist force Cortical excitability of Ipsilesional M1(TMS) Follow-up: 30 days